sirna Latest News

SMi's Controlled Release conference returns to London for the 10th year running with an expert speaker faculty and an all-new programme for 2013.

Small interfering RNAs (siRNAs) are a potent new drug class that can silence a disease-causing gene, but delivering them to a target cell can be challenging.

Biocroi, the Dublin-based biotech company has recently received €800k in funding to further its work on a unique range of multi-well microplates. These are for use in drug discovery research in the pharmaceutical and bio industries.

Join the top 50 Pharma companies as they discuss some of the most prominent issues that stand in the way of the successful harnessing of the vast potential that this process possesses.

Despite the Nobel Prize-winning discovery of RNA interference (RNAi) over a decade ago and the billions of dollars spent developing therapeutic applications, delivery issues continue to challenge the field

Select Biosciences - RNAi Asia - Register today

Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects

Many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to activate an immune response.